Taking a look at Pressure BioSciences, Inc., a leader in the development and sale of broadly enabling sample preparation solutions using their patented pressure cycling technology (or PCT) platform, they announced in February the award of over $1 million dollars in non-dilutive grant funding from the National Human Genome Research Institutes of the National Institutes of Health (NIH). The grant will help fund development of automated systems, enabling significantly better control of DNA fragmentation, which is a critical step in the preparation of samples for Next Generation Sequencing (NGS) Platforms. The award of this DNA grant offers Pressure BioSciences a rapid and affordable entrance into the expanding genomic marketplace. NGS is one of the fastest growing, multi-billion dollar segments of the life sciences, offering the promise of significant discoveries and improvements in human healthcare, particularly personalized medicine.